

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Beredjiklian 1



Section 1. Identifying Inform	nation					
Given Name (First Name) Pedro	2. Surname (Last Nar Beredjiklian	ne)		3. Date 06-September-2019		
4. Are you the corresponding author? ✓ Yes No						
5. Manuscript Title Three Dimensional Printing in Orthopa	aedic Surgery: Technol	logy and Clinical	Applications	S		
6. Manuscript Identifying Number (if you k JBJS-D-19-00877R1	now it)					
Section 2. The Work Under C	Consideration for P	ublication				
Did you or your institution at any time rectany aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of interesting the submitted work (including statistical analysis, etc.)?	g but not limited to gran	nts, data monitorin <u>o</u> No	g board, stud			
Relevant financia	l activities outside	the submitted	work.			
Place a check in the appropriate boxes of compensation) with entities as desc clicking the "Add +" box. You should re	ribed in the instruction eport relationships tha —	ns. Use one line fo It were present d	or each entit	ty; add as many lines as you need by		
Are there any relevant conflicts of inter- If yes, please fill out the appropriate in		No				
ii yes, piease iiii out the appropriate iiii						
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments		
Rothman Institute and related properties			✓ St	ock options		
Natador, Inc			✓ St	ock Options		
Dimension Orthotics, LLC			✓ St	ock Options		
hieme			✓ Ro	pyalties		
Elsevier			✓ Ro	oyalties		

Beredjiklian 2



Section 4. Intel	lectual Property P	atents & Copyrig	ghts			
Do you have any paten If yes, please fill out the Excess rows can be rem	appropriate information	on below. If you hav	•		Yes No he "ADD" button to add	a row.
Patent?	Pending? Is	sued? Licensed?	Royalties Lic	ensee?	Comments	
US20170216078A1	✓					
Section 5. Pola	tionships not cover	ed above				
	·		: to be : in floor			
Are there other relation potentially influencing,	-	•	eive to nave influe	enced, or that	give the appearance of	
Yes, the following re	elationships/conditions	c/circumstances are	present (explain	below):		
✓ No other relationsh	ips/conditions/circums	tances that present	a potential confl	lict of interest		
At the time of manuscri On occasion, journals m					ate their disclosure state ps.	ments.
Section 6. Discl	osure Statement					
Based on the above dis below.	closures, this form will a	automatically gene	rate a disclosure	statement, wh	ich will appear in the bo	х
Dr. Beredjiklian reports Orthotics, LLC, other fro patent US20170216078	om Thieme, other from				or, Inc, other from Dimen , Dr. Beredjiklian has a	sion

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Beredjiklian 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Lutsky 1



Section 1.	Identifying Inform	nation		
1. Given Name (Fi Kevin	rst Name)	2. Surname (Last Name) Lutsky		3. Date 05-September-2019
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Nam Pedro Beredjiklian	ne
5. Manuscript Title Three Dimension		edic Surgery: Technology a	and Clinical Applications	
6. Manuscript Ider JBJS-D-19-00877	ntifying Number (if you kr 'R1	now it)		
			-	
Section 2.	The Work Under C	onsideration for Public	cation	
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grants, da	a third party (government, com Ita monitoring board, study desi	nmercial, private foundation, etc.) for sign, manuscript preparation,
Section 3.	Delevent financial		b.ua:sea ala.ula	
Place a check in t of compensation clicking the "Add	the appropriate boxes i	ibed in the instructions. Us port relationships that wer	ether you have financial rela	ntionships (regardless of amount dd as many lines as you need by onths prior to publication.
Section 4.	Intellectual Proper	rty Patents & Copyric	ahts	
Do you have any	patents, whether plan	ned, pending or issued, br	roadly relevant to the work?	Yes ✓ No

Lutsky 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Lutsky has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Lutsky 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation				
1. Given Name (First Name) Alexander	2. Surname (Last Vaccaro	Name)		3. Date 06-September-2019	
4. Are you the corresponding author?	☐ Yes ✓ N	Correspon Pedro Ber	ding Author's Nar edjiklian	me	
5. Manuscript Title Three Dimensional Printing in Orthopae	dic Surgery: Tech	nology and Clinical	Applications		
6. Manuscript Identifying Number (if you known JBJS-D-19-00877R1	ow it)				
Section 2. The Work Under Co	nsideration fo	Publication			
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to g				c.) for
Section 3. Relevant financial a	activities outsid	le the submitted	work.		
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	oed in the instructort relationships st? Yes [tions. Use one line fo	or each entity; a	dd as many lines as you need	d by
			_		
Name of Entity	Grant? Persor	Non-Financial Support?	Other? Con	nments	
Advanced Spinal Intellectual Properties			✓ Stock	Options	
Aesculap			Royalt	ies	
AO Spine			■ Board	Membership	
Atlas Spine			Consu	ıltant; Royalties	
Avaz Surgical			✓ Stock	Options	
Bonovo Orthopaedics			✓ Stock	Options	
Clinical Spine Surgery			€ditor		
Computational Biodynamics			✓ Stock	Options	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Cytonics				✓	Stock Options
DePuy		✓			Consultant
Dimension Orthotics LLC				✓	Stock Options
Electrocore				✓	Stock Options
Elsevier		✓			Royalties
Flagship Surgical				✓	Board Membership; Stock Options
FlowPharma				✓	Stock Options
ranklin Bioscience				✓	Stock Options
Globus		✓		✓	Consultant; Royalties; Stock Options
nnovative Surgical Design		✓			Consultant; Board Membership; Stock Options
nsight Therapeutics				✓	Stock Options
aypee					Royalties
Medtronic		\checkmark			Consultant; Royalties
Nuvasive		✓		✓	Consultant; Stock Options
Orthobullets		✓			Consultant
Paradigm Spine				✓	Stock Options
Parvizi Surgical Innovation				✓	Board Membership; Stock Options
Prime Surgeons				✓	Board Membership; Stock Options
Progressive Spinal Technologies				✓	Board Membership; Stock Options
Replication Medica				✓	Stock Options
Rothman Institute and Related Properties				✓	Stock Options
Spine Journal				✓	Editor
Spine Medica				✓	Stock Options
Spine Therapy Network Inc				✓	Board Membership
pineWave		✓			Consultant; Royalties
Spinology				✓	Stock Options
itout Medical		✓		✓	Consultant; Stock Options
Stryker Spine		✓			Consultant; Royalties
aylor Francis/Hodder and Stoughton		✓			Royalties



Thieme				✓			Royaltie	s; Editorial Boa	ırd	
Vertiflex						✓	Stock O	otions		
Sentryx						✓	Board M	embership		
Section 4.	Intellectual	Property	Patents	& Copyri	ghts					
Do you have any If yes, please fill Excess rows can	out the appropr	iate informat	tion belov	w. If you ha	•			✓ Yes the "ADD" bu	No utton to add	a row.
Pater	nt?	Pending?	Issued <mark>?</mark>	Licensed ?	Royalties?	License	ee?	Comments		
US20170216078A1		✓								
Section 5.	Relationshi	ps not cove	ered abo	ove						
Are there other operations are therefore the potentially influence and the control of the contro	•				eive to have i	influence	d, or tha	t give the ap	pearance of	
Yes, the follo	wing relationsh	ips/condition	ns/circum	nstances are	e present (exp	olain belo	ow):			
✓ No other rela	ationships/cond	itions/circum	nstances t	that presen	t a potential (conflict c	f interes	t		
At the time of m On occasion, jou									closure state	ments.



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Vaccaro reports other from Advanced Spinal Intellectual Properties, personal fees from Aesculap, other from AO Spine, personal fees from Atlas Spine, other from Avaz Surgical, other from Bonovo Orthopaedics, other from Clinical Spine Surgery, other from Computational Biodynamics, other from Cytonics, personal fees from DePuy, other from Dimension Orthotics LLC, other from Electrocore, personal fees from Elsevier, other from Flagship Surgical, other from FlowPharma, other from Franklin Bioscience, personal fees and other from Globus, personal fees from Innovative Surgical Design, other from Insight Therapeutics, from Jaypee, personal fees from Medtronic, personal fees and other from Nuvasive, personal fees from Orthobullets, other from Paradigm Spine, other from Parvizi Surgical Innovation, other from Prime Surgeons, other from Progressive Spinal Technologies, other from Replication Medica, other from Rothman Institute and Related Properties, other from Spine Journal, other from Spine Medica, other from Spine Therapy Network Inc, personal fees from SpineWave, other from Spinology, personal fees and other from Stout Medical, personal fees from Stryker Spine, personal fees from Taylor Francis/Hodder and Stoughton, personal fees from Thieme, other from Vertiflex, other from Sentryx, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Wang 1



Section 1. Identifying Info	ormation	
1. Given Name (First Name) Mark	2. Surname (Last Name) Wang	3. Date 05-September-2019
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Pedro Beredjiklian
5. Manuscript Title Three Dimensional Printing in Ortho	opaedic Surgery: Technology a	and Clinical Applications
6. Manuscript Identifying Number (if yo JBJS-D-19-00877R1	u know it)	
		_
Section 2. The Work Unde	r Consideration for Public	cation
	ding but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant finance	ial activities outside the s	submitted work.
of compensation) with entities as de	escribed in the instructions. Us I report relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by the present during the 36 months prior to publication.
Section 4. Intellectual Pro		
Intellectual Pro	perty Patents & Copyric	hts
Do you have any patents, whether p	lanned, pending or issued, br	oadly relevant to the work? Yes V No

Wang 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Wang has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Wang 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Rivlin 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Michael	2. Surname (Last Name) Rivlin	3. Date 29-July-2019
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Pedro Beredjiklian, MD
5. Manuscript Title Three Dimensional Printing in Orthopae	edic Surgery: Technology a	and Clinical Applications
6. Manuscript Identifying Number (if you kn JBJS-D-19-00877R1	now it)	
Section 2. The Work Under Co	onsideration for Public	cation
		a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of interest	est?	
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	ibed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of intere		
If yes, please fill out the appropriate info		
Name of Entity	Grant? Personal Fees? S	n-Financial other? Comments
Dimension Orthotics, LLC		
Section 4. Intellectual Proper	rty Patents & Copyrig	ghts
Do you have any patents, whether plan		
If yes, please fill out the appropriate info		oddry relevant to the work: Y Tes 110

Rivlin 2



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
JS20170216078	✓						
							_
Section 5. Relationshi	ps not cov	ered ab	ove				
Are there other relationships or potentially influencing, what yo				eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	nips/conditio	ns/circur	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	itions/circur	nstances	that presen	t a potential	conflict of interes	st	
At the time of manuscript accep On occasion, journals may ask a							nents.
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ll automa	atically gene	erate a disclo	sure statement, v	vhich will appear in the bo	K
Dr. Rivlin reports other from Dir US20170216078 pending.	mension Ortl	notics, LL	C, outside t	he submitte	d work; In additic	on, Dr. Rivlin has a patent	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Rivlin 3